VANCOUVER, British Columbia — Shares of AbCellera Biologics Inc. surged more than 30% Monday after the clinical-stage biotechnology company announced positive top-line results from a Phase 2 trial of its experimental menopause drug, ABCL635, sending the stock to its highest level in months.

The stock closed up 30.32% at $9.03, with volume of more than 12.7 million shares, well above its three-month average of roughly 7.2 million shares, lifting the company’s market capitalization to about $2.76 billion. The rally came after AbCellera said before the market opened that its Phase 2 study evaluating ABCL635 for moderate-to-severe vasomotor symptoms, more commonly known as hot flashes, had met its primary efficacy endpoints.

ABCL635 is an investigational antibody designed to target NK3R, a receptor found on a specific set of neurons in the hypothalamus that plays a role in regulating body temperature. The drug is being developed as a non-hormonal, long-acting, subcutaneous treatment, an approach the company has positioned as a potential alternative to existing hormone-based therapies for menopause symptoms.

The randomized, double-blind, placebo-controlled trial enrolled 92 postmenopausal women who were experiencing an average of roughly 10 moderate or severe hot flashes per day. Participants were randomly assigned to receive either a single 600-milligram subcutaneous dose of ABCL635 or a placebo. At week four, the treatment group saw hot flash frequency drop by a mean of 8.8 events per day from baseline, compared with a 3.5 event reduction in the placebo group, a placebo-adjusted difference of 5.3 events that was statistically significant. In percentage terms, ABCL635 reduced hot flash frequency by 83% on average, compared with a 33% reduction for placebo.

The drug also showed a significant effect on symptom severity, with treated patients seeing severity scores fall by 1.4 points on average compared with 0.3 points for placebo, and meaningful improvements were observed in patient-reported sleep quality and overall impression of symptom change. AbCellera said the drug was well tolerated over the four-week treatment period, with no serious adverse events, severe adverse events, or discontinuations due to side effects. The most common adverse events among patients receiving the treatment were headache, fatigue and injection site reactions.

Dr. JoAnn V. Pinkerton, a professor of obstetrics and gynecology at the University of Virginia School of Medicine who specializes in women’s midlife health, said the four-week data set “a new efficacy benchmark for the reduction of hot flashes both in frequency and severity.” She added that if the results are validated in a larger Phase 3 trial, the drug could offer patients a more convenient dosing option with potentially less toxicity than existing treatments.

Sarah Noonberg, AbCellera’s chief medical officer, described the results as a milestone both for the company and for women’s health more broadly. She said the data show that by targeting the NK3 receptor with an antibody, the company has demonstrated “potential best-in-class vasomotor symptom relief over four weeks with a single subcutaneous dose.”

The trial results carry particular significance for AbCellera because ABCL635 represents the company’s first internally developed drug candidate to advance into Phase 2 testing, marking a shift for a company that built its early business primarily around providing antibody discovery technology and services to pharmaceutical partners rather than developing its own drugs. Vasomotor symptoms affect an estimated 80% of women during menopause, according to figures cited by the company, with the majority describing their symptoms as moderate to severe. AbCellera estimates roughly 12 million women in the United States experience moderate-to-severe hot flashes, of which more than 6 million seek treatment, underscoring the size of the potential market opportunity if the drug advances successfully through later-stage trials and regulatory review.

Monday’s surge builds on a period of already elevated investor interest in AbCellera. The company’s shares had climbed more than 136% year-to-date heading into the results, according to recent analysis of the stock’s performance, reflecting growing attention to the company’s pipeline as it has increasingly emphasized internal drug development alongside its existing antibody discovery partnerships. AbCellera has also struck a series of collaboration deals in recent months, including a multispecific antibody partnership with Vertex Pharmaceuticals and prior agreements with Jazz Pharmaceuticals and AbbVie, deals the company has said brought in more than $110 million in upfront payments combined.

The company reported second-quarter 2026 financial results on August 5, ahead of Monday’s trial data, showing revenue of roughly $4.05 million, down sharply from the prior year, alongside a widened net loss of $55.4 million. AbCellera has said it holds approximately $567 million in cash and more than $675 million in total available liquidity, which the company has said supports at least three years of continued investment across its pipeline.

Following Monday’s results, AbCellera hosted an investor conference call to discuss the Phase 2 data in greater detail and outline next steps for ABCL635’s development, including plans for further validation in a larger Phase 3 trial. Analysts covering the stock had already shown signs of growing optimism ahead of the data release, with several firms raising their price targets on the shares in the days leading up to Monday’s announcement.

With ABCL635 emerging as the company’s most advanced internally developed program, Monday’s results are likely to serve as a key reference point for how investors value AbCellera’s broader pipeline going forward, particularly as the company continues to balance its established antibody discovery business against the larger financial risks and potential rewards associated with advancing its own drug candidates through clinical development.

Brent crude was steady near $87.70 a barrel on Tuesday after gaining about 10% over the previous four sessions. The advance in oil weighed on Treasuries, pushing the benchmark 10-year yield up six basis points to 4.71% in the previous session. There will be no cash trading in Treasuries during Asian hours Tuesday due to a Japan holiday.

Early focus in Asia is on the yen after the currency weakened 1% on Monday, erasing about half of its recent intervention-led rally. The move is psychologically significant for traders, who remain on alert for further official support. The yen was slightly stronger in early Tuesday trading at about 159.17 per dollar.

Elsewhere, Asian stocks and equity-index futures for US benchmarks edged lower. Australian government bonds fell ahead of an expected policy-rate hold by the central bank. Gold extended its advance for a third day, trading at about $4,400 an ounce.

Read more: IPO Rush: 34 companies race to launch issues worth Rs 45,000 crore by September 30

Live Events

Oil’s rally over the past week, amid little progress toward easing tensions in the Middle East, has revived worries over price pressures after Friday’s softer US jobs data tempered expectations for an immediate Federal Reserve interest-rate hike. Attention now turns to Wednesday’s US consumer price index report, which may offer fresh signals on the path for interest rates.
“The jobs report may have eased some anxieties about a Fed rate hike next month, but those concerns could hit new highs without cooler-than-expected inflation numbers this week,” said Chris Larkin at E*Trade from Morgan Stanley.
While stocks had seen a burst of enthusiasm about a possible reopening of Hormuz, markets may be less likely to respond positively to vague reports about progress in talks, he said.

President Donald Trump lashed out against Iran’s demands for compensation as part of talks to wind down the conflict, dimming hopes of a quick agreement that would reopen the strait. Trump had signaled on Sunday that he was prepared to let economic pressure on Iran build, rather than launch fresh strikes.

The closely watched consumer price index is seen rising 0.1% in July following a 0.4% decline in the prior month, based on the median projection in a Bloomberg survey of economists ahead of Wednesday’s Bureau of Labor Statistics release.

Fed Bank of Cleveland President Beth Hammack told Yahoo Finance it’s possible that a number of rate hikes may be needed to bring inflation down to the target.

“I would say in general, one 25-basis-point move probably doesn’t do a whole lot for the economy,” Hammack said Monday in an interview with Yahoo Finance. “So it’s probably some number,” but “I don’t want to prejudge what that number is going to be.”

Operator

At this time, I would like to welcome everyone to AlTi’s Second Quarter 2026 Earnings Conference Call. I would like to advise all parties that this conference is being recorded and a replay of the webcast is available on AlTi’s Investor Relations website. Now at this time, I will turn things over to [ Jeff Schoenborn ] with AlTi Investor Relations. Please go ahead.

Unknown Executive

Good afternoon and welcome to AlTi Global’s Second Quarter 2026 earnings conference call. On today’s call, we will hear prepared remarks from Nancy Curtin, Interim Chief Executive Officer and Global Chief Investment Officer, as well as Pat Keenan, Chief Financial Officer. They will be joined by Kevin Moran, our President and Chief Operating Officer, for the Q&A session.

Before we begin, I would like to remind everyone that certain statements made during the call may be deemed forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, comments made during the prepared remarks and in response to questions. Forward-looking statements can be identified by the use of words such as anticipate, believe, continue, estimate, expect, future, intend, may, plan, and will, or similar terms.

Because these forward-looking statements involve both known and unknown risks and uncertainties, there are important factors that could cause actual results to differ materially from those expressed or implied by these statements. For a discussion of the risks and uncertainties that

President Donald Trump’s social media company reported a loss of $238m (£176m) between April and June as it branched into ventures unrelated to media, including cryptocurrencies.

The quarterly loss is more than 10 times the amount reported during the same period a year earlier, according to the Trump Media and Technology Group, which runs the President’s Truth Social platform.

The firm says it will refocus on its social media mission, which includes a controversial service that offers faster access to Trump’s market-moving posts to paying customers.

The group’s interim chief executive officer Kevin McGurn said on Monday that more than 10 customers have signed up for the new service.

The BBC has contacted Trump Media and Technology Group and the White House for further comment.

The company posted $1.7m in revenue, which it said is up 89% from the same period a year before, but suffered overall loss dure to the drop in cryptocurrencies.

It added that it closed the second quarter with total assets of $2bn and financial assets of around $1.9bn, which includes cash, short-term investments and digital currencies.

The group has yet to turn a profit, even as it expands into areas including cryptocurrency holdings and clean-energy investments.

In July, it announced a plan to give Wall Street traders faster access to Trump’s posts on Truth Social, widely viewed as a way to give subscribers an edge in trading stocks and other heavily traded assets.

The move has prompted a series of legal questions and ethical musings, including whether it is right that a company – of which the president’s family remains the majority shareholder – stands to profit from his own public statements.

The new service is “expected to provide the company with a new revenue stream,” Trump Media said in its earnings statement on Monday.

McGurn said: “I’m encouraged by this momentum, and shareholders should expect more frequent communication from us on our progress each quarter as we enter this next chapter.”

Copyright ©2026 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8